CN117715657A - B7-h3抗体的药物组合物及其用途 - Google Patents

B7-h3抗体的药物组合物及其用途 Download PDF

Info

Publication number
CN117715657A
CN117715657A CN202280050225.0A CN202280050225A CN117715657A CN 117715657 A CN117715657 A CN 117715657A CN 202280050225 A CN202280050225 A CN 202280050225A CN 117715657 A CN117715657 A CN 117715657A
Authority
CN
China
Prior art keywords
pharmaceutical composition
cancer
composition
present
container
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280050225.0A
Other languages
English (en)
Chinese (zh)
Inventor
周岩
K·萨姆帕库马尔
S·J·伯克
X·王
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Macrogenics Inc
Original Assignee
Macrogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc filed Critical Macrogenics Inc
Publication of CN117715657A publication Critical patent/CN117715657A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN202280050225.0A 2021-07-16 2022-07-06 B7-h3抗体的药物组合物及其用途 Pending CN117715657A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163222750P 2021-07-16 2021-07-16
US63/222,750 2021-07-16
PCT/US2022/073462 WO2023288173A1 (en) 2021-07-16 2022-07-06 Pharmaceutical compositions of a b7-h3 antibody and use of the same

Publications (1)

Publication Number Publication Date
CN117715657A true CN117715657A (zh) 2024-03-15

Family

ID=84920541

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280050225.0A Pending CN117715657A (zh) 2021-07-16 2022-07-06 B7-h3抗体的药物组合物及其用途

Country Status (11)

Country Link
US (1) US20240336687A1 (https=)
EP (1) EP4370155A4 (https=)
JP (1) JP2024526773A (https=)
KR (1) KR20240038005A (https=)
CN (1) CN117715657A (https=)
AU (1) AU2022310668A1 (https=)
CA (1) CA3224118A1 (https=)
IL (1) IL310187A (https=)
MX (1) MX2024000690A (https=)
TW (1) TW202310874A (https=)
WO (1) WO2023288173A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012501751A1 (en) * 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
WO2019246312A1 (en) * 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
BR112022019073A2 (pt) * 2020-03-25 2022-11-08 Jiangsu Hengrui Pharmaceuticals Co Ltd Composição farmacêutica que compreende conjugado anticorpo-fármaco e uso da mesma

Also Published As

Publication number Publication date
CA3224118A1 (en) 2023-01-19
AU2022310668A1 (en) 2024-01-18
IL310187A (en) 2024-03-01
MX2024000690A (es) 2024-02-07
WO2023288173A1 (en) 2023-01-19
EP4370155A4 (en) 2025-06-11
JP2024526773A (ja) 2024-07-19
KR20240038005A (ko) 2024-03-22
US20240336687A1 (en) 2024-10-10
EP4370155A1 (en) 2024-05-22
TW202310874A (zh) 2023-03-16

Similar Documents

Publication Publication Date Title
JP7473603B2 (ja) 液体医薬組成物
AU2013334740A1 (en) Stable, low viscosity antibody formulation
CN113194993A (zh) 含高浓度抗vegf抗体的蛋白质溶液配制品
Maeder et al. Local tolerance and stability up to 24 months of a new 20% proline-stabilized polyclonal immunoglobulin for subcutaneous administration
CN117715657A (zh) B7-h3抗体的药物组合物及其用途
US12364756B2 (en) Pharmaceutical compositions of a PD-1 antibody and use of the same
US11459399B2 (en) Pharmaceutical compositions of a HER2/neu antibody and use of the same
HK40112469A (zh) Pd-1抗体的药物组合物及其用途
TW202237185A (zh) Ｈｅｒ２／ｎｅｕ抗體的藥物組合物及其用途
CN116916952A (zh) HER2/neu抗体的药物组合物及其用途
HK40102521A (zh) Her2/neu抗体的药物组合物及其用途
US20230053747A1 (en) Pharmaceutical Compositions of a HER2/neu Antibody and Use of the Same
WO2025140467A1 (zh) 稳定的高浓度抗pd-1抗体药物制剂
EA050933B1 (ru) Фармацевтические композиции антитела к pd-1 и применение указанной композиции
TW202523354A (zh) 抗體製劑
HK40005809B (en) Liquid pharmaceutical composition

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination